Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing cell and gene therapies for life-threatening diseases. The Companyâs lead clinical program is for prademagene zamikeracel (pz-cel), its investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Companyâs fully integrated cell and gene therapy Good Manufacturing Practice (cGMP) manufacturing facility served as the manufacturing site for pz-cel used in its Phase III VIITAL trial and is capable of supporting commercial production of pz-cel upon FDA approval. The Companyâs development portfolio also features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. The Companyâs novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases.

Employees

136

Sector

Pharmaceuticals

Calendar

Aug. 17 - Q2 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
25-06-12	6.245 $	+0.40%	547,963
25-06-11	6.220 $	-3.72%	798,199
25-06-10	6.460 $	-1.22%	754,627
25-06-09	6.540 $	-2.97%	1,065,355
25-06-06	6.740 $	+4.01%	940,100

Delayed Quote Nasdaq, June 12, 2025 at 04:00 pm EDT

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.245USD

Average target price

19.93USD

Spread / Average Target

+219.11%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 04:00:00 2025-06-12 pm EDT			5-day change	1st Jan Change
6.245 ^USD	+0.40%		-3.63%	+12.12%

Jun. 02	Abeona Therapeutics Announces New Employee Inducement Grants	RE
May. 15	Abeona Therapeutics Inc., Q1 2025 Earnings Call, May 15, 2025

Capitalization	319M 276M 260M 235M 435M 27.36B 490M 3.02B 1.18B 12.57B 1.2B 1.17B 45.92B	P/E ratio 2025 *	-62.5x	P/E ratio 2026 *	45.7x
Enterprise value	319M 276M 260M 235M 435M 27.36B 490M 3.02B 1.18B 12.57B 1.2B 1.17B 45.92B	EV / Sales 2025 *	6.67x	EV / Sales 2026 *	3.01x
Free-Float	94.88%	Yield 2025 *	-	Yield 2026 *	-

Abeona Therapeutics Announces New Employee Inducement Grants	Jun. 02	RE
Abeona Therapeutics Inc., Q1 2025 Earnings Call, May 15, 2025	May. 15
Abeona Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	May. 15	CI
Abeona Therapeutics And Lurie Children's Open First Center For Zevaskyntm Gene Therapy	May. 14	RE
Abeona Therapeutics to Sell Zevaskyn Priority Review Voucher for $155 Million; Shares Rise	May. 12	MT
Abeona Therapeutics Enters Into Agreement To Sell Priority Review Voucher	May. 12	RE
An undisclosed buyer entered into a definitive asset purchase agreement to acquire Rare Pediatric Disease Priority Review Voucher of Abeona Therapeutics Inc. for approximately $160 million.	May. 11	CI
U.S. Food and Drug Administration Approves Abeona Therapeutics' ZEVASKYN accelerates momentum and expands treatment options for the EB community	Apr. 29	CI
Abeona Therapeutics Says US FDA Approves Zevaskyn to Treat Wounds in Patients With Genetic Skin Disease	Apr. 29	MT
US FDA approves first cell-based gene therapy for rare genetic skin disorder	Apr. 29	RE
Abeona Therapeutics Inc. - Special Call	Apr. 29
US FDA Approves ZEVASKYN, First And Only Cell-Based Gene Therapy For Patients With Recessive Dystrophic Epidermolysis Bullosa	Apr. 29	RE
US FDA approves Abeona's skin disorder therapy	Apr. 29	RE

Stifel Starts Abeona Therapeutics With Buy Rating, $21 Price Target	24-05-30	MT
Cantor Fitzgerald Adjusts Price Target on Abeona Therapeutics to $21 From $36, Maintains Overweight Rating	24-05-16	MT
Cantor Fitzgerald Adjusts Price Target on Abeona Therapeutics to $40 From $22, Maintains Overweight Rating	22-11-08	MT
Alliance Global Starts Abeona Therapeutics at Buy With $20 Price Target	22-09-15	MT
SVB Securities Adjusts Price Target on Abeona Therapeutics to $5 From $1, Maintains Market Perform Rating	22-08-12	MT

Abeona Therapeutics Inc. Stock

Equities

ABEO

US00289Y2063

Pharmaceuticals

Valuation: Abeona Therapeutics Inc.

Chart: Abeona Therapeutics Inc.

Latest news: Abeona Therapeutics Inc.

Last Transcript: Abeona Therapeutics Inc.

Analysts' recommendations: Abeona Therapeutics Inc.

Press Releases: Abeona Therapeutics Inc.

News in other languages: Abeona Therapeutics Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Abeona Therapeutics Inc.

ETFs: Abeona Therapeutics Inc.

Biopharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Jun. 02	AQ
Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference	May. 30	AQ
Abeona Therapeutics: Q1 Earnings Snapshot	May. 15	AQ
Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates	May. 15	AQ
UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder	May. 14	AQ

En bourse, vers l'infini et au-delà	Jun. 04
Bourse : gueule de bois pour Rémy Cointreau, un départ chez Valneva et du solide chez HP Enterprise	Jun. 04
Bourse : Bouygues et Alstom publient, Atos se projette, Burberry et Microsoft dégraissent	May. 14
La Bourse aime (aussi) les bulldozers	May. 14
Pfiou, c'est compliqué	Feb. 05

1 day	+0.40%
1 week	-3.63%
Current month	+0.08%
1 month	+11.52%
3 months	+11.72%
6 months	+5.67%
Current year	+12.12%

1 week	6.1	6.84
1 month	5.31	7.17
Current year	3.93	7.32
1 year	3.93	7.32
3 years	2.19	9.01
5 years	2.19	94.75
10 years	2.19	568.75

Manager	Title	Age	Since
Vishwas Seshadri CEO	Chief Executive Officer	49	2021-10-14
Joseph Vazzano DFI	Director of Finance/CFO	41	2022-03-13
Amanda Moore CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Michael Amoroso CHM	Chairman	47	2021-10-13
Mark Alvino BRD	Director/Board Member	57	2006-02-28
Faith Charles BRD	Director/Board Member	63	2021-03-24

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ABEONA THERAPEUTICS INC.	+0.40%	-3.63%	+38.78%	+47.03%	319M
CSL LIMITED	-0.91%	-1.26%	-17.05%	-9.54%	76.11B
SAMSUNG BIOLOGICS CO.,LTD.	-1.34%	+2.90%	+38.68%	+26.88%	53.99B
UCB	+1.80%	+2.40%	+22.58%	+108.94%	35.97B
BIOGEN INC.	-0.56%	+1.50%	-42.63%	-33.01%	19.39B
INNOVENT BIOLOGICS, INC.	-0.06%	+10.32%	+122.62%	+212.79%	16.99B
ALTEOGEN INC.	+0.61%	+11.40%	+48.73%	+849.13%	16.17B
INTRA-CELLULAR THERAPIES, INC.	-0.04%	-.--%	+93.36%	+148.72%	14.02B
INCYTE CORPORATION	+0.54%	+2.94%	+15.48%	-1.68%	13.4B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-1.29%	-14.99%	-0.57%	-28.26%	11.75B
Average	-0.08%	+1.57%	+32.00%	+132.10%	25.81B
Weighted average by Cap.	-0.32%	+1.38%	+20.03%	+89.49%

	2025 *	2026 *
Net sales	47.91M 41.39M 38.97M 35.26M 65.23M 4.1B 73.47M 453M 177M 1.88B 180M 176M 6.89B	106M 91.62M 86.26M 78.06M 144M 9.08B 163M 1B 391M 4.17B 398M 389M 15.24B
Net income	3.74M 3.24M 3.05M 2.76M 5.1M 321M 5.74M 35.39M 13.82M 147M 14.05M 13.75M 538M	8.72M 7.53M 7.09M 6.42M 11.87M 747M 13.37M 82.4M 32.17M 343M 32.71M 32.02M 1.25B
Net Debt	-	-